Screening for Research Subjects With Anterior Segment Diseases
NCT00088348 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600
Last updated 2017-07-02
Summary
This study will identify patients with anterior segment disease who may be eligible to participate in current or future NEI studies on this disease. Anterior segment disease includes all disorders that affect the eye surface, anterior chamber, iris and ciliary body and lens of the eye. The eye surface is composed of the cornea, conjunctiva, eyelids, lacrimal and meibomian glands, and the interconnecting nerves.
Patients of any age with anterior segment disease may be eligible for this screening study. Participants will be evaluated with some or all of the following tests and procedures, depending on the nature of their eye problem:
* Medical history and brief physical examination.
* Eye examination, including measurement of visual acuity (eye chart) and eye pressure, examination of the pupils, eye movements, structures in the front of the eye (cornea, conjunctive, etc.), the lens, and the structures in the back of the eye (retinal, optic nerve, etc.).
* Photographs of the eye to help assess the status of the cornea and conjunctive and to evaluate any changes that may occur in the future.
* Assessment of tear and surface status. The amount of tears the eyes can produce is measured by placing a small piece of sterile paper in the corner of the eye every 5 minutes. Special orange and green dyes are placed in the eyes to determine the health status of the surface of the eye.
* Corneal or conjunctival biopsy. A small tissue sample from the surface of the eye may be removed for laboratory examination to help diagnose a condition that is unclear. For this procedure, the eye is numbed with anesthetic eye drops. The required tissue is collected, an antibiotic ointment is placed in the eye to prevent infection, and a patch may be placed over the eye for 12 to 24 hours.
* Blood draw for tests to study the cause of the patient's eye disease.
* Other diagnostic tests as needed.
* DNA testing to look for a genetic pattern associated with the patient's eye disease.
Patients who are found eligible for an NEI study will be offered participation in that study. Patients who are not eligible for current studies will be advised about treatment options.
Conditions
- Eye Diseases
Sponsors & Collaborators
-
National Eye Institute (NEI)
lead NIH
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-07-13
- Completion
- 2008-08-20
Countries
- United States
Study Locations
More Related Trials
-
Detection of Neutralizing Antibodies in Patients Treated With Bevacizumab or Ranibizumab
NCT00605943 ·Status: COMPLETED
-
Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration
NCT02843490 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Aflibercept on Human Corneal Endothelial Cells in Neovascular Age-Related Macular Degeneration
NCT03313401 ·Status: COMPLETED
-
Immune Indicators of Uveitis
NCT00089739 ·Status: COMPLETED
-
A Research Study to Evaluate the Effects of Repeated Intravitreal Injections on Bacteria Around the Eye
NCT01531842 ·Status: UNKNOWN ·Phase: NA
-
Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery
NCT00769145 ·Status: COMPLETED ·Phase: PHASE1
-
Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
NCT00070759 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
NCT04853251 ·Status: RECRUITING ·Phase: PHASE4
-
Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate
NCT00349739 ·Status: NO_LONGER_AVAILABLE
-
A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis
NCT00404885 ·Status: COMPLETED ·Phase: PHASE3
-
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
NCT00058994 ·Status: COMPLETED ·Phase: PHASE3
-
Metalloproteinases and Recurrent Corneal Erosion Syndrome
NCT02891694 ·Status: COMPLETED
-
Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye
NCT00063765 ·Status: COMPLETED ·Phase: PHASE1
-
UNICORNS: Uveitis in Childhood Prospective National Cohort Study
NCT05385757 ·Status: ACTIVE_NOT_RECRUITING
-
Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant vs Standardized Therapy
NCT00468871 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Outcome of Treatment of Uveitis With Biologic Drugs in Resistant Cases Vogt-koyanagi-Harada Disease
NCT05349747 ·Status: UNKNOWN
-
Uveitis Gene-Expression Profiling
NCT00874471 ·Status: COMPLETED
-
A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal CNV Associated With Wet AMD in Patients That Require Persistent Anti-VEGF Therapy
NCT00809419 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants
NCT07218770 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior Uveiti
NCT00876434 ·Status: COMPLETED ·Phase: PHASE1
-
Biomarkers in Ocular Inflammation and Uveitis
NCT04690829 ·Status: COMPLETED
-
Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis
NCT00043667 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration.
NCT01831947 ·Status: COMPLETED ·Phase: PHASE4
-
Daclizumab and Sirolimus to Treat Uveitis
NCT00078689 ·Status: COMPLETED ·Phase: PHASE1
-
A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
NCT02387957 ·Status: TERMINATED ·Phase: PHASE2